The Solution 2.0

Description

No description information is available for the drug.

Uses and Indications

This drug is indicated for the temporary relief of symptoms associated with hemorrhoids, hemorrhoidal tissues, or piles. The symptoms alleviated by this medication include itching, pain, soreness, and burning.

There are no teratogenic or nonteratogenic effects associated with this drug.

Dosage and Administration

The affected area should be cleansed with mild soap and warm water prior to application. After cleansing, it is essential to rinse well or pat the area dry using an appropriate cleansing pad. The area must then be gently dried by patting or blotting with toilet tissue or a soft cloth before the application of the product.

For adults and children aged 12 years and over, the product should be applied externally to the affected area using the spray pump. The recommended frequency of application is up to four times daily. It is important to adhere to this frequency and not to exceed the directed usage.

Contraindications

Use is contraindicated in individuals who are unable to keep the product out of reach of children. In the event of accidental ingestion, immediate medical assistance should be sought by contacting a poison control center.

Warnings and Precautions

For external use only. Healthcare professionals should advise patients to consult a doctor or pharmacist prior to use if they have any of the following conditions: heart disease, high blood pressure, thyroid disease, diabetes, difficulty in urination, or if they are taking medication for high blood pressure or are experiencing depression.

When administering this product, it is imperative to avoid inserting it into the rectum using fingers, mechanical devices, or applicators, as this may lead to complications.

Patients should be instructed to discontinue use and seek medical advice if any of the following occur: bleeding, worsening of the condition, or lack of improvement within 7 days. Additionally, they should be vigilant for symptoms such as redness, irritation, swelling, pain, weakness, confusion, headache, difficulty breathing, or changes in skin color (pale, grey, or blue). These symptoms may indicate methemoglobinemia, a rare disorder that can manifest up to 2 hours after application.

It is essential to keep this product out of reach of children. In the event of accidental ingestion, immediate contact with a poison control center or medical assistance is necessary.

Side Effects

Patients using this product should be aware that it is for external use only. Prior to use, it is advised to consult a doctor or pharmacist if the patient has a history of heart disease, high blood pressure, thyroid disease, diabetes, difficulty in urination, is taking medication for high blood pressure, or has a history of depression.

During the use of this product, it is critical to avoid inserting it into the rectum using fingers, mechanical devices, or applicators. Patients are instructed to discontinue use and seek medical advice if any of the following occur: bleeding, worsening of the condition or lack of improvement within 7 days, or the emergence of redness, irritation, swelling, pain, or other concerning symptoms. Additionally, patients should seek immediate medical attention if they experience weakness, confusion, headache, difficulty breathing, or pale, grey, or blue-colored skin, as these may be indicative of methemoglobinemia, a rare disorder that can manifest up to 2 hours after application.

Drug Interactions

There are currently no documented drug interactions associated with this medication. Additionally, there is no information available regarding interactions with laboratory tests. As such, no specific recommendations for dosage adjustments or monitoring are warranted at this time.

Packaging & NDC

Below are the non-prescription pack sizes of The Solution 2.0 (lidocaine). Columns show Packaging, Formulation Type, and Active Ingredient Strength.

Pediatric Use

Pediatric patients should be advised to keep this medication out of reach of children. In the event of accidental ingestion, it is crucial to contact a poison control center or seek medical assistance immediately.

The medication is indicated for use in adults and children aged 12 years and older. There are no specific dosage adjustments or safety data provided for children under 12 years of age. Therefore, its use in this population is not recommended.

Geriatric Use

Elderly patients may not have specific information regarding the use of this medication, including dosage adjustments, safety concerns, or special precautions. Therefore, healthcare providers should exercise caution when prescribing this medication to geriatric patients. It is advisable to monitor these patients closely for any potential adverse effects or changes in efficacy, given the lack of targeted data for this population.

Pregnancy

The safety of this product during pregnancy has not been established. Use is contraindicated in pregnancy due to potential risks to the fetus. There may be risks associated with the use of lidocaine during pregnancy; therefore, it is essential for healthcare providers to be consulted for advice regarding its use.

Dosage adjustments may be necessary for pregnant individuals, and medical guidance should be sought to ensure appropriate management. Pregnant women are advised to discuss the use of this product with their healthcare provider before use to evaluate the potential benefits and risks.

Lactation

There are no specific warnings or precautions regarding the use of this product in lactating mothers. Additionally, there is no information available about the potential for excretion in breast milk or any associated risks to breastfed infants.

Renal Impairment

Patients with renal impairment have not been specifically addressed in the available prescribing information. There are no dosage adjustments, special monitoring requirements, or safety considerations outlined for individuals with reduced kidney function. Healthcare professionals should exercise caution and consider the lack of data when prescribing to this patient population.

Hepatic Impairment

Patients with hepatic impairment have not been specifically studied in relation to the use of this medication. Consequently, there are no established dosage adjustments, special monitoring requirements, or precautions outlined for individuals with compromised liver function. It is recommended that healthcare providers exercise caution when prescribing this medication to patients with hepatic impairment, given the lack of data on its safety and efficacy in this population. Regular monitoring of liver function may be prudent in these cases, although specific parameters are not defined in the available information.

Overdosage

In the absence of specific overdosage information, it is essential for healthcare professionals to remain vigilant regarding the potential for overdose with this medication. In cases where an overdose is suspected, immediate medical attention should be sought.

Healthcare providers are advised to monitor patients closely for any signs or symptoms that may indicate an overdose. These may include, but are not limited to, increased severity of known side effects, altered mental status, or any unusual physiological responses.

Management of an overdose should be guided by the clinical presentation of the patient. Supportive care is paramount, and symptomatic treatment should be initiated as necessary. It is recommended that healthcare professionals consult local poison control centers or relevant toxicology resources for specific guidance on managing overdose cases.

In summary, while no specific overdosage information is available, healthcare professionals should exercise caution, remain alert to potential overdose symptoms, and implement appropriate management strategies as needed.

Nonclinical Toxicology

No teratogenic or non-teratogenic effects have been reported in the available nonclinical studies. Additionally, there is no information regarding animal pharmacology and toxicology. The absence of data limits the assessment of potential risks associated with the use of the compound in these contexts.

Postmarketing Experience

During postmarketing experience, the following adverse reactions have been reported voluntarily or through surveillance programs. Methemoglobinemia, a rare disorder, has been noted, with onset potentially occurring up to 2 hours after use.

Patient Counseling

Healthcare providers should advise patients to keep this medication out of reach of children. It is crucial to emphasize that if the medication is swallowed, patients must call a poison control center or seek medical assistance immediately. This information is vital for ensuring the safety of both patients and their families.

Storage and Handling

The product is supplied in various package configurations, with specific NDC numbers available for identification. It is essential to store the product at room temperature, maintaining a range of 15° to 30°C. Proper storage conditions are crucial to ensure the integrity and efficacy of the product.

Additional Clinical Information

Patients should apply the medication using a spray pump to the affected area, with a maximum frequency of up to four times daily. It is important for patients to adhere to the directed usage and not exceed the recommended application frequency. No additional information is available regarding laboratory tests, abuse potential, patient counseling, or postmarketing experience.

Drug Information (PDF)

This file contains official product information for The Solution 2.0, including active ingredients, dosage, warnings, and labeling as submitted by the manufacturer for OTC distribution.

View product document (PDF)